{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:24:25Z","timestamp":1790918665925,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,12,27]],"date-time":"2006-12-27T00:00:00Z","timestamp":1167177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The objective of this study was to evaluate the effect of a treatment with venlafaxine on the expression of multidrug resistance\u2010associated protein (<jats:italic>MRP)<\/jats:italic> gene and multidrug resistance\u2010related proteins (<jats:italic>MDR<\/jats:italic>) in human colon carcinoma cells (Caco\u20102) compared to a known P\u2010glycoprotein (PGY1) inducer, rifampine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Caco\u20102 cells were treated with venlafaxine (50\u2009\u00b5M, 100\u2009\u00b5M, 250\u2009\u00b5M, and 500\u2009\u00b5M) and rifampin (25\u2009\u00b5M and 50\u2009\u00b5M) to test the possible induction of <jats:italic>MRP<\/jats:italic> and <jats:italic>MDR<\/jats:italic> expression. The treatment times used were 1.5, 3, 6, 12, 24, 48, and 72 h. RNA was isolated from the cells, and <jats:italic>MDR<\/jats:italic> and <jats:italic>MRP<\/jats:italic> genes were amplified using PCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both venlafaxine and rifampine had the most dramatic effect at the 50\u2009\u00b5M concentration. There was an increase in <jats:italic>MDR<\/jats:italic> and <jats:italic>MRP<\/jats:italic> expression in Caco\u20102 cells after the acute treatment (1.5, 3, and 6 h) with venlafaxine. These results were similar to those with rifampine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PGY1 contributes to renal and biliary elimination of drugs by transporting the drug out of the cell and back into the intestinal lumen, where drugs may be further metabolized by intestinal enzymes such as Cytochrome P (CYP)\u2010450 3A4. Its function is to limit the bioavailability of orally administered compounds. Due to the increase in <jats:italic>MDR<\/jats:italic> and <jats:italic>MRP<\/jats:italic> gene expression seen after the acute treatment with venlafaxine, there could be a potential drug\u2013drug interaction with other medications that are metabolized via CYP450\u20133A4 when coadministered with venlafaxine. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.820","type":"journal-article","created":{"date-parts":[[2006,12,27]],"date-time":"2006-12-27T10:47:17Z","timestamp":1167216437000},"page":"49-53","source":"Crossref","is-referenced-by-count":31,"title":["Venlafaxine induces P\u2010glycoprotein in human Caco\u20102 cells"],"prefix":"10.1002","volume":"22","author":[{"given":"M. J.","family":"Ehret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. M.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rathinavelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,12,27]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199018030-00004"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1360704"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2004.05.006"},{"key":"e_1_2_1_5_1","first-page":"HS\u20109","article-title":"Tracy TS. Role of cytochrome P450 3A subfamily in drug interactions","volume":"22","author":"Cupp MJ.","year":"1997","journal-title":"US Pharmacist"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cb.08.110192.000435"},{"key":"e_1_2_1_7_1","doi-asserted-by":"crossref","first-page":"14991","DOI":"10.1016\/S0021-9258(18)82429-2","article-title":"Functional expression of P\u2010glycoprotein in apical membranes of human intestinal Caco\u20102 cells","volume":"268","author":"Hunter J","year":"1993","journal-title":"J Biol Chem"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1081\/DMR-120001389"},{"key":"e_1_2_1_9_1","first-page":"62","article-title":"A pharmacokinetic drug\u2010drug interaction study of venlafaxine and indinavir","volume":"35","author":"Levin GM","year":"2001","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342010-00003"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.10.010"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03830.x"},{"key":"e_1_2_1_13_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.2042-7158.2003.tb02434.x","article-title":"Gene expression of CYP3A4, ABC\u2010transporters (MDR1 and MRP1\u2010MRP5) and hPXR in three different human colon carcinoma cell lines","volume":"55","author":"Pfunder A","year":"2003","journal-title":"J Pharm Pharmacol"},{"key":"e_1_2_1_14_1","unstructured":"RasbandWS.1997\u20132005.ImageJ U.S. National Institutes of Health Bethesda Maryland USA.http:\/\/rsb.info.nih.gov\/ij\/."},{"key":"e_1_2_1_15_1","first-page":"311","article-title":"Modulators and substrates of P\u2010glycoprotein and cytochrome P4503A coordinately up\u2010regulate these proteins in human colon carcinoma cells","volume":"49","author":"Schuetz EG","year":"1996","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.9.4001"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809502900612"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.046532"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.19.8822"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.820","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T01:13:42Z","timestamp":1700010822000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,27]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["10.1002\/hup.820"],"URL":"https:\/\/doi.org\/10.1002\/hup.820","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12,27]]}}}